TCT roundup: Stents, TAVR and more

Sessions on third-generation stents and transcatheter aortic valve replacement devices were among the hottest draws at this year's Transcatheter Cardiovascular Therapeutics meeting, developments few could have foreseen at the first TCT event 25 years ago. "It was envisioned at that time as a relatively small boutique meeting to discuss the implementation of new device angioplasty, beyond balloon angioplasty," said SCAI fellow Dr. Gregg W. Stone, TCT co-director. "At the first TCT, stents were mentioned as an afterthought." According to SCAI fellow Dr. Herbert Aronow, a number of practice-changing developments were presented at TCT, including findings from the EUROMAX bivalirudin trial, compelling data on renal denervation and innovations such as drug-coated balloons in angioplasty.

View Full Article in:

CardiovascularBusiness.com · Diagnostic & Interventional Cardiology magazine